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introduction
An understanding of  the epidemiology of  Mycobacterium 
tuberculosis is critical for effective control. In this, the 
first article of  a series, the global burden of  tuberculosis 
(TB), risk factors for transmission and the epidemiology 




Mycobacterium tuberculosis is a 
member of  the Mycobacterium 
complex; the other members 
being Mycobacterium africanum 
and Mycobacterium bovis.
Mycobacterium africanum is 
most commonly found in West 
Africa; it causes up to a quarter 
of  cases of  tuberculosis in the 
Gambia (1). The symptoms of  
infection resemble those of  M. 
tuberculosis. The infectivity is 
similar to M. tuberculosis, and 
it is an important opportunistic 
pathogen in the setting of  
advanced immunosuppression 
due to HIV or other causes. Management is identical to 
the management for disease due to M. tuberculosis.
Mycobacterium bovis is the main cause of  tuberculosis in 
cattle, deer, and other mammals. The human bacillus 
may have arisen from M. bovis in the setting of  animal 
domestication (2). Human M. bovis infection generally 
occurs in the setting of  consumption of  infected cow’s 
milk products, Bacille Calmette-Guérin (BCG) vaccination 
for TB prevention, or intravesicular BCG installation for 
bladder cancer treatment.                                                                      
Burden of tuberculosis
The epidemiology of  tuberculosis varies substantially 
around the world. The highest rates (100/100,000 or 
higher) are observed in sub-Saharan Africa, India, China, 
and the islands of  Southeast Asia and Micronesia (Figure 
1). Estimates provided by USAID in 2007 for South 
Sudan were 228 cases per 100,000 population. In South 
Sudan, an estimated 18,500 people develop TB, and 5,300 
die of  TB annually (3). 
Poverty, HIV and drug resistance are major contributors 
to the resurging global TB epidemic (4, 5). Approximately 
95% of  TB cases occur in developing countries. 
Approximately 1 in 14 new TB cases occur in individuals 
who are infected with HIV; 85 percent of  these cases occur 
in Africa. An estimated half  million cases of  multidrug 
resistant (MDR)-TB also occur annually in Africans; even 
higher rates of  drug resistant disease occur in Eastern 
Europe.
risk factors
Some people develop TB disease within weeks of  
becoming infected before their immune system can fight 
the TB bacteria.  Other people may get sick years later, 
when their immune system becomes weak for another 
reason (6).
Overall, about 5 to 10% of  infected persons who do not 
receive treatment for latent TB infection will develop TB 
disease at some time in their lives. For persons whose 
immune systems are weak, especially those with HIV 
infection, the risk of  developing TB disease is much 
Figure 1. Estimated tuberculosis cases 2007 (Source: ©WHO http://www.health.qld.gov.au/qtbcc/
images/TB2009WHO.JPG)
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higher than for those with normal immune systems.
Generally, persons at high risk for developing TB disease 
fall into two categories (7):
Persons who have been recently infected with TB 1. 
bacteria.
Persons with medical conditions that weaken the 2. 
immune system.
1. Persons who have been recently infected with TB 
bacteria
These include:
Persons who have close contacts with a person with • 
infectious TB disease.
Persons who have immigrated from areas of  the • 
world with high rates of  TB.
Children less than 5 years of  age who have a positive • 
TB test.
Persons from groups with high rates of  TB • 
transmission, such as homeless persons, injection 
drug users, and persons with HIV infection.
Persons who work or reside with people who are at • 
high risk of  TB in facilities or institutions such as 
hospitals, homeless shelters, correctional facilities, 
nursing homes and residential homes for those with 
HIV.
2. Persons with medical conditions that weaken the 
immune system
Babies and young children often have weak immune 
systems.  Other people can have weak immune systems 





Severe kidney disease.• 
Low body weight.• 
Organ transplants.• 
Head and neck cancer.• 
Medical treatments such as corticosteroids or organ • 
transplant.
• Specialized treatment for rheumatoid arthritis or 
Cohn’s disease.
In South Sudan although the exact incidence of  HIV/
AIDS among TB cases is not known, HIV prevalence 
appears to be on the rise. Data from limited population 
surveys show HIV prevalence rates range between 1 and 
8 percent among the general population, with higher rates 
(up to 25 percent) found in border towns. Multidrug-
resistant (MDR) TB cases account for around 1.9 percent 
of  new cases and usually occurs among defaulters and 
relapse cases.
The TB epidemic is an outgrowth of  a long-standing 
war, which has resulted in poverty, malnutrition, and a 
large number of  displaced populations and refugees. 
Destruction of  health infrastructure, lack of  microscopic 
services, and displacement or lack of  health personnel 
have also contributed to the epidemic (3).
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